1.
|
Phase: Phase IV, Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: UKALL2003, NCT00222612
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL01, NCT00198991
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 15 Sponsor: Other Protocol IDs: GMALL05, NCT00199082
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 to 75 Sponsor: Other Protocol IDs: CGC05MK1002, NCT00188149
|
|
6.
|
Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 6 months to 21 years Sponsor: Other Protocol IDs: SHEBA-06-4013-IK-CTIL, NCT00339118
|
|
7.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: Hemato INCAN 01/2007, NCT00429065
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: YUNZHI-BC, NCT00647075
|
|
9.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1. NHL, non, NCT00969462
|
|
10.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: RJ-2010-56, NCT01358253
|
|
11.
|
Phase: Phase IV Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P0334, NCT01501487
|
|
12.
|
Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: A11-3691, NCT01537029
|
|
13.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Approved-not yet active Age: 20 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2011-91, NCT01571518
|
|
14.
|
Phase: Phase IV Type: Treatment Status: Active Age: 20 to 70 Sponsor: Other Protocol IDs: 4-2011-0068, NCT01660542
|
|
15.
|
Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011-3, NCT01664975
|
|
16.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: UARK 2003-26, NCT00090493
|
|
17.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 12 to 80 Sponsor: Other Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
|
|
18.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 59 Sponsor: Other Protocol IDs: M09TNM, 2009-015238-31, NCT01057069
|
|
19.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-62091, 2009-014889-26, EU-21059, PMAR-EORTC-62091, SARC-020, TRUSTS, EUDRACT-2009-014889-26, NCT01189253
|
|
20.
|
Phase: Phase III, Phase II Type: Natural history/Epidemiology, Supportive care Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 201010HBV, NCT01210287
|
|
21.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
|
|
22.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172
|
|
23.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: PUMCH-Breast- AX, NCT01415336
|
|
24.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: DLBS1425-0310, NCT01433562
|
|
25.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: ISG/OS-2, 2011-001659-36, NCT01459484
|